Total
0
Shares
Orthocell (ASX:OCC) - Managing Director, Paul Anderson (left) - The Market Herald
Managing Director, Paul Anderson (left)
Source: Orthocell
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Orthocell (OCC) is a step closer to market after gaining Conformity Assessment approval from the Therapeutic Goods Administration (TGA)
  • The company's CelGro bone and tissue regeneration tech is now expected to be authorised for commercialisation in Australia early next year
  • According to the company, the final market approval assessment is "largely administrative," so the product is likely to hit Australian shelves in early 2021
  • With approval already granted in Europe and Australia seemingly not far behind, Orthocell Managing Director Paul Anderson says the U.S. is the next target
  • Orthocell is up 1.19 per cent, trading for 42.5 cents

Orthocell (OCC) is a step closer to market after gaining Conformity Assessment approval from the Therapeutic Goods Administration (TGA).

The company's CelGro bone and tissue regeneration tech is now expected to be authorised for commercialisation in Australia early next year.

Big tick

The TGA has completed its review of the company’s regulatory application, confirming CelGro complies with the requirements of the Medical Device Regulations (Conformity Assessment).

The Conformity Assessment included a review of Orthocell’s quality management system and manufacturing processes.

According to the company, the final Market Approval assessment is "largely administrative," so the product is likely to hit Australian shelves in early 2021.

Orthocell has also progressed its application to the Prostheses List Advisory
Committee, which would enable patient costs for CelGro to be reimbursed by insurers. The company is hoping to be included on the Prostheses List by the end of next year.

With approval already granted in Europe and Australia seemingly not far behind, Orthocell Managing Director Paul Anderson says the company is next gunning for approval in the U.S.

"This is an important milestone for the company as we continue to commercialise our collagen medical device platform and I am excited to complete this important step towards gaining Australian and U.S. Food and Drug Administration (FDA) regulatory approval," Paul said.

Outlook

Orthocell is now well positioned to market the CelGro tech to the global market, with FDA approval expected sometime during 2021.

The company believes CelGro represents a breakthrough in bone and tissue reconstruction, with clinical studies and market feedback indicating a best-in-class product in terms of patient outcomes.

Having surpassed the important TGA milestone, Orthocell is a step closer to market for its new cornerstone product.

Orthocell is up 1.19 per cent, trading for 42.5 cents at 1:19 pm AEDT.

OCC by the numbers
More From The Market Herald
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald

" Little Green Pharma (ASX:LGP) pursues global expansion over June quarter

Little Green Pharma (LGP) celebrated backing from Gina Rhineheart and a major medicinal cannabis facility purchase over the June quarter but noted subdued

" Chimeric Therapeutics (ASX:CHM) obtains licence for solid tumour cell therapy

Chimeric Therapeutics (CHM) has obtained the exclusive licence to a novel treatment for solid tumours from the University of Pennsylvania.  
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) strikes UK distribution deal for COVID-19 test tech

Surface chemistry company AnteoTech (ADO) has struck its first European distribution deal for its EuGeni rapid diagnostic test (RDT) technology.
Medlab Clinical (ASX:MDC) - CEO, Dr Sean Hall - The Market Herald

" Medlab Clinical (ASX:MDC) gets green light for US patent

Medlab Clinical (MDC) has been issued with a notice of allowance by the United States Patent Office (USPTO) regarding a patent for its